Introduction
The hematology-oncology unit is characterized by the admission of patients with variable degrees of immunosuppression and the administration of myelosuppressive medications that predispose patients to infections, making antibiotic resistance a critical issue in patient care. 1, 2 Antibiotic cycling is among the proposed strategies to prevent antibiotic resistance. It consists of scheduled changes of antibiotic use with removal of an antibiotic from routine use and re-introduction later, alternating with other antibiotics in an attempt to maintain heterogeneous pressure over the bacterial flora of the hospital and, theoretically, prevent the emergence of resistance. 3 Since the early studies with aminoglycosides cycling performed by Gerding et al. 4, 5 antibiotic cycling has been suggested as a significant tool to prevent antibiotic resistance. Multiple studies followed in different clinical settings (mainly intensive care units) that have shown decreased incidence of late-onset hospital acquired pneumonia, decreased mortality and decreased antibiotic resistance. [6] [7] [8] Despite these encouraging results, some studies have shown no significant difference with antibiotic cycling, and currently there are no clear evidence-based guidelines to implement a successful antibiotic cycling strategy. 9, 10 The effect of antibiotic cycling on the clinical isolates on the hematology-oncology and bone marrow transplant population has not been well studied. One previous study in this population showed a decreased incidence of resistance among Gram-negative isolates but an increase in enterococcal isolates. 11 Herein, we evaluated the feasibility of implementation and the effect of antibiotic cycling on clinical isolates (pre-intervention and post-intervention) over a 5-year period in a hematology-oncology unit, compared with the entire period in the solid organ transplant intensive care unit (TICU), which had no antibiotic cycling intervention.
Methods

Setting
This study was performed in an 11-bed hematologyoncology unit with an active bone marrow transplant program located at a university-affiliated tertiary care hospital. This unit houses patients with hematological and solid organ malignancies that receive chemotherapy. We included the TICU as a comparison group, in terms of percentage of susceptible isolates, since these patients are also prone to develop serious infections, require prolonged immunosuppression and are frequently exposed to broadspectrum antibiotics. The TICU includes kidney, liver, lung, pancreas and heart transplant patients.
Antibiotic cycling and usage
Cycling of antibiotics for the empiric treatment of neutropenic fever at the hematology-oncology unit was implemented in 1999 and consisted of scheduled 3 months rotation between cefepime and piperacillin-tazobactam (pip-tazo) for empiric therapy. The daily census from 1997 to 2004 was obtained from the Hematology division. Compliance with the protocol was ensured through education of the housestaff and reminders by the unit pharmacy and by the use of pre-printed orders that included the specific dates of antibiotic cycling at the time of the patient's admission. There were no restrictions on the prescription of either antibiotic. There was no antibiotic cycling effort in the TICU. Standard precautions and infection control measures were promoted in both units by the same infection control team. Empiric and preoperative therapy in the TICU varied by the transplant performed. In liver transplants, cefepime and fluconazole were given for 72 h, for kidney transplant the regimen included cefazolin and nystatin, for pancreas transplant it included cefepime and fluconazole. Lung transplants received prophylactic cefepime, clindamycin, voriconazole and inhaled amphotericin B. If the patient was re-admitted, initial empiric therapy was typically cefepime or pip-tazo þ /Àa quinolone. There were no cefepime or pip-tazo use restrictions.
Data on the of antibiotic use were gathered from the medication billing system (in grams) and the defined daily dose (DDD) was assumed to be 3.375 g of pip-tazo four times a day from 1998 to 2002 (no data available in 1997) and 4.5 g four times a day in 2003 (due to changes in medication preparation) and 1 g IV three times a day for cefepime. There was a manufacturer's shortage of pip-tazo during a period of 6 months in 2002. The index of the cefepime/pip-tazo consumption was defined as DDD per 1000 patient-days of cefepime/pip-tazo use.
Microbiological data
Microbiological data were extracted from a computergenerated database provided by the Clinical Microbiology Laboratory that included all the clinical bacterial isolates from the hematology-oncology unit and TICU (from January 1997 to June 2004), including bacterial identification and antibiotic susceptibilities. Susceptibility testing was performed using the Kirby-Bauer disk diffusion method (CLSI, Wayne, PA, USA), or the Vitek 2 instrument (bioMerieux Inc., Durham, NC, USA). Enteric pathogens (Escherichia coli, Klebsiella pneumoniae, Enterobacter spp.) were analyzed individually and as a group. Only clinical isolates were included and, if multiple cultures were positive for a single organism on the same patient, only the first one was considered for the study.
Statistical analysis
Poisson regression models were used to calculate the rate of susceptibility per 1000 patient-days, and further to test whether the overall susceptibility rate during 1999-2004 is significantly different from that during 1997-1998 in terms of the rate ratio and corresponding 95% confidence intervals. Trend analyses for susceptible rates from 1999 to 2004 were fit in Poisson regression with time in years as the independent predictor and the log (rate) as the dependent variable. Comparison of the susceptibility percentages among isolates between post-intervention (1999-2004) and pre-intervention (1997-1998) periods was assessed by w 2 test, expressed in odds ratio of susceptibility for post-vs pre-intervention. The linear trend of susceptibility percentages over post-intervention years was evaluated in the logistic regression. Percentages of susceptible isolates were compared between the hematology-oncology unit and TICU on a similar manner. All statistical analyses were performed with Proc GENMOD and Proc Logistic in SAS 9.1. A P-value o0.05 was considered statistically significant. Two-sided 95% CIs were calculated for all rate ratio estimates.
Results
Clinical isolates and program implementation
Gram-positive bacteria were more commonly isolated than Gram-negatives, although there was a significant increase in the rate of isolation of Enterococcus spp. between the post-and pre-intervention periods (pre-intervention: 32/ 1000 patient-days; post-intervention: 125/1000 patientdays; OR: 1.7, 95% CI: 1.15-2.51, P ¼ 0.007). There was no significant change in the isolation rate among Gramnegative enterics, P. aeruginosa, Staphylococcus aureus or coagulase-negative Staphylococcus (total number of isolates pre-intervention: 46, 17, 53, 64, respectively; post-intervention: 157, 40, 121, 157, respectively, P40.05).
The successful implementation of the program by education and information is reflected by the index of the cefepime/pip-tazo consumption, which changed from 0.003 in 1998 to 0.88 in 2003. The use of cefepime increased significantly from 960 to 167 976 mg/1000 patient-days, 1998-2003 (Po0.0001).
Susceptibility among hematology-oncology unit isolates Among Gram-negative enteric pathogens, there was not a significant change in susceptibility to cefepime (OR: 3.4, 95% CI: 0.2-56.2), or pip-tazo (OR: 1.98, 95% CI: 0.74-5.32, P ¼ 0.17) (Figure 1a ). There was no significant change in the susceptibility of P. aeruginosa to cefepime or pip-tazo (OR: 0.77, 95% CI: 0.07-7.98 and OR: 0.56, 95% CI: 0.06-5.44, respectively; Figure 1b) .
In Enterococcus spp., there was a decrease in susceptibility to ampicillin (OR: 0.40, 95% CI: 0.18-0.89, P ¼ 0.02) and vancomycin (OR: 0.23, 95% CI: 0.09-0.58, P ¼ 0.001) (Figure 2 ). Trend analysis did not show significant changes.
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There was a significant decrease in S. aureus susceptibility to clindamycin (OR: 0.14, 95% CI: 0.05-0.38) and erythromycin (OR: 0.44, 95% CI: 0.21-0.90). There was no significant change in susceptibility to oxacillin (OR: 0.78, 95% CI: 0.38-1.61) or trimethoprim-sulfamethoxazole (OR: 0.32, 95% CI: 0.07-1.49). The decrease in susceptibility to oxacillin among the coagulase-negative Staphylococcus was not significant (OR: 0.57, 95% CI: 0.31-1.01). 
Susceptibility of hematology-oncology unit isolates compared to TICU isolates
Discussion
The role of antibiotic cycling in controlling the emergence of antibiotic resistance remains to be defined. While several studies have suggested that it can be effective in decreasing antibiotic resistance in a unit, other studies have shown no effect, and there are many unanswered questions.
4,6-11
The first issue limiting such a program is the difficulty of implementing the protocol and guaranteeing compliance with the protocol. With the help of the pharmacy and proper education, it can be performed in the community or in the academic setting. 12, 13 Furthermore, our study documented that it is feasible to maintain an active and successful program during a prolonged period of time despite constant changes in the housestaff and attending staff rotating through the service. The efforts of pharmacists were particularly helpful in reminding physicians of the protocol and current antibiotics in use. In our study, the use of cefepime and pip-tazo was more evenly distributed after the cycling protocol was instituted.
The optimal duration and the antibiotics employed for antibiotic cycling are not entirely clear. Evans et al.
14 compared dual antibiotic rotation (DAR) with single antibiotic rotation (SAR) for suspected Gram-negative infections in the ICU setting. The DAR included empirical cycling regimens for pneumonia and peritonitis. They found that SAR was associated with increased resistance among Gram-negatives when compared to DAR, although the poor compliance with the protocol during SAR (71%) makes results difficult to interpret. They also included carbapenems and fluoroquinolones in the cycling protocol, which may have themselves altered the levels of resistance among isolates.
14 On a study in an adult hematologyoncology unit, Dominguez et al.
11 used antibiotic cycling and were able to maintain susceptibility of Gram-negative and Gram-positive organisms over time, with no major changes in the Gram-negative clinical isolates except for a significant decline in Enterobacter cloacae. The effectiveness of antibiotic cycling to maintain Gramnegative susceptibility has been shown in previous studies but randomized, controlled trials of rigorous design are scarce. 6, 9 Bergstrom et al. 15 developed a mathematical model to evaluate the effectiveness of antibiotic cycling to prevent resistance. Based on their model, when the selection pressure fluctuates less often (cycling) than usual (mixing) a bacterial clone has higher chance of adaptation and survival. 15 However, this study assumes that mixing is constants and does not acknowledges that the physician may prefer a single broad-spectrum antibiotic.
Cycling regimens within the same antibiotic class have been studied even less often. In fact, most of the studies performed antibiotic cycling including different classes of antibiotics in the cycling periods. 16 In our study, with the use of two different b-lactam antibiotics, susceptibility remained stable among enteric and P. aeruginosa over the study period. Furthermore, the susceptibilities were significantly better maintained when compared with the TICU. In the study performed by Martinez et al. 17 in ICU patients, there was an important difference in the incidence of resistance of P. aeruginosa during cycling periods compared to mixing periods and a tendency toward increased resistance to carbapenems and ceftazidime during mixing periods.
Antibiotic cycling can influence the prevalence of resistance on wards to which patients are transferred from the area of intervention. This is probably achieved by decreasing multi-resistant nosocomial infections in patients outside the intervention unit, not participating in the cycling protocol. 18 Warren et al. 10 failed to show any changes in P. aeruginosa and Gram-negative enterics resistance in the ICU setting, but the rest of the hospital had a decrease in susceptibility over the same period of time.
Potential adverse effects of antibiotic cycling have to be considered before implementation of these protocols. Antibiotic cycling is not always effective in controlling emergence of antibiotic resistance during the study period. Van Loon et al. 19 evaluated the acquisition of resistance to three antibiotics during a cyclic protocol (cefpirome, piptazo or levofloxacin) and found that bacteria tended to be less susceptible to levofloxacin and pip-tazo during cycling periods of exposure to each of these antibiotics, likely related to the homogeneous pressure of the antibiotic, but they did not find a major increment in cross-resistance between the antibiotics that were off the cycle. In the previous hematology-oncology unit study as well as in our study, cycling has been related to an increase in the number of Gram-positive (enterococcal) infections, although this seems to be occurring in other hematology-oncology units despite different infection control measures or antibiotic use. 1, 11, 20 Over the past four decades, Gram-positive bacteria have become the leading cause of bacteremia at the bone marrow transplant units and our unit has followed this trend. 1 Furthermore, in our study we observed an increment in the number of Enterococcus spp. isolates, associated with increased resistance. Dominguez et al.
11
also reported an increase in Enterococcus spp., but they did not find increase in resistance. The study by Bruno-Murtha et al. 12 found an association between vancomycin-resistant Enterococcus (VRE) and beta-lactam antibiotic use during cycling. However, the low overall prevalence of VRE precluded the authors from making a firm conclusion. The use of broad-spectrum antibiotics without activity against Enterococcus spp. during the cycling protocol may be associated with depletion of the normal intestinal flora and with increased colonization by enterococci. 21 Whether there is a cause-effect between cycling and VRE emergence is less clear. 22 On one hand, the use of anaerobic coverage (pip-tazo) has been associated with increased incidence of VRE colonization after its use, during the period of recovery of the original gut microflora. [23] [24] [25] On the other hand, a previous study by Bradley et al. 22 found a decreased incidence of VRE while cycling ceftazidime and pip-tazo. A sample of VRE isolates collected from our hematologyoncology unit during our study period was found to be primarily clonal by pulsed-field gel electrophoresis analysis (data not shown). Thus, clonal dissemination at least contributed to the increase in VRE during this time period. Neither of the cycled agents used in our study (cefepime and pip-tazo) have activity against VRE, so antibiotic selection may have played a role separate from the issue of antibiotic cycling itself.
We recognize that this study has some limitations. It is a retrospective study using a historical cohort and an uncontrolled comparison group. Furthermore, clinical isolates in a hematology-oncology unit are known to change over time. 26 Also, this study was not designed to evaluate the effect of the clinical isolates on patients' outcomes, hospital length of stay, morbidity or mortality. However, little data and experience are available on antibiotic cycling in this antibiotic resistance-prone population and more studies are needed.
We conclude that an antibiotic cycling program can be implemented in a bone marrow transplant unit and may maintain or decrease levels of resistance among Gramnegative pathogens (enterics and P. aeruginosa). VRE may increase, but this may be due to multiple factors including promotion of colonization by the cycling protocol and/or lapses in infection control.
